

Zeitschrift:	Jahrbuch der Schweizerischen Naturforschenden Gesellschaft. Wissenschaftlicher und administrativer Teil = Annuaire de la Société Helvétique des Sciences Naturelles. Partie scientifique et administrative
Herausgeber:	Schweizerische Naturforschende Gesellschaft
Band:	162 (1982)
Artikel:	Induction of endogenous virogenes and oncogenes in the pathogenesis of leukemia
Autor:	Moroni, Christoph
DOI:	https://doi.org/10.5169/seals-90894

Nutzungsbedingungen

Die ETH-Bibliothek ist die Anbieterin der digitalisierten Zeitschriften auf E-Periodica. Sie besitzt keine Urheberrechte an den Zeitschriften und ist nicht verantwortlich für deren Inhalte. Die Rechte liegen in der Regel bei den Herausgebern beziehungsweise den externen Rechteinhabern. Das Veröffentlichen von Bildern in Print- und Online-Publikationen sowie auf Social Media-Kanälen oder Webseiten ist nur mit vorheriger Genehmigung der Rechteinhaber erlaubt. [Mehr erfahren](#)

Conditions d'utilisation

L'ETH Library est le fournisseur des revues numérisées. Elle ne détient aucun droit d'auteur sur les revues et n'est pas responsable de leur contenu. En règle générale, les droits sont détenus par les éditeurs ou les détenteurs de droits externes. La reproduction d'images dans des publications imprimées ou en ligne ainsi que sur des canaux de médias sociaux ou des sites web n'est autorisée qu'avec l'accord préalable des détenteurs des droits. [En savoir plus](#)

Terms of use

The ETH Library is the provider of the digitised journals. It does not own any copyrights to the journals and is not responsible for their content. The rights usually lie with the publishers or the external rights holders. Publishing images in print and online publications, as well as on social media channels or websites, is only permitted with the prior consent of the rights holders. [Find out more](#)

Download PDF: 06.02.2026

ETH-Bibliothek Zürich, E-Periodica, <https://www.e-periodica.ch>

Induction of endogenous virogenes and oncogenes in the pathogenesis of leukemia

Christoph Moroni

Introduction

Oncogenic retroviruses fall into two classes, those with slow and those with acute transforming ability. The former are termed leukemia viruses; they induce leukemia after about 3–12 months following virus inoculation. The latter are termed sarcoma- or acute leukemia viruses. Their effect becomes obvious after 1–2 weeks after inoculation. They transform fibroblasts and other suitable target cells *in vitro*. This is in contrast to the leukemia viruses which do not display transforming activities *in vitro*. The important difference between the two classes of viruses is that the sarcoma viruses, but not the leukemia viruses, carry additional genes, called oncogenes, which control neoplastic transformation. Interestingly, these oncogenes are normal cellular host genes which have found their way into the viral genome via recombination. In other words, sarcoma viruses have evolved from non-transforming retroviruses by recombination with host oncogenes. It is the “picked up” oncogene which controls and directs the malignant phenotype (for references and review see Weiss et al., 1982). In vertebrate cells, the oncogenes are thought to carry out normal functions of still unknown nature, while under the control of the viral genome they cause transformation.

The first mammalian leukemia virus was isolated by Gross from AKR mice (Gross, 1951). It was only 20 years later that it was realized that all mice carry in their genomes multiple copies of integrated retroviral genomes, collectively called endogenous viruses. Nucleic acid hybridisation (“Southern blot”) analyses shows that mice carry about 15–25 viral copies related to the Gross leukemia virus. They are inherited as normal cellular genes, following Mendel’s laws and appear to be subject to normal gene regula-

tion by the host (Aaronson and Stephenson, 1977). They offer a model to study gene expression in eukaryotic cells.

There is heterogeneity amongst endogenous viruses. (In this article, we deal only with the endogenous viruses related to leukemia viruses). Many copies show deletions and are therefore defective. When expressed, they may lead to production of viral proteins, but not to infectious virus. The complete infectious viruses of inbred mice fall into two groups, distinguishable by their host range. Xenotropic viruses replicate in non-mouse, e.g. rabbit cells, but not in mouse cells (Levy, 1973; Levy, 1978), while ecotropic viruses show the reciprocal behaviour (Pincus et al., 1971). There is recombination amongst endogenous viruses. In leukemogenesis, an ecotropic virus recombines with a (presumably defective) virus related to the xenotropic group to generate a dual-tropic virus which replicates both in mouse- and non-mouse cells (Hartley et al., 1977).

In retroviral leukemogenesis the following steps can be distinguished: First, there is expression and high-titer replication of ecotropic viruses. This can be achieved by spontaneous induction of the ecotropic viral loci as in AKR mice, or, when these loci are silent or absent, by passive inoculation of an ecotropic viral stock. In AKR mice, later in life, the endogenous xenotropic virus becomes expressed, and with the onset of the characteristic T-cells thymoma the dual-tropic virus appears (Rowe et al., 1980). It may be that only this latter virus has the ability to infect the target cell for neoplastic transformation. It is thought that the long latency of this disease is related to the time required to generate the dual-tropic virus and to infect the appropriate target cell. How does a virus lacking known transforming genes induce transformation? From work with avian leukosis virus, which also lacks




Fig. 1. Minimum model of retroviral leukemogenesis

oncogenes, we know that following infection viral DNA can integrate next to a cellular *onc* gene, in this case the *myc* gene (Hayward et al., 1981). Viral control elements called LTR (see Diggelmann, this volume) containing promoter sequences can then induce the transcription of the neighbouring *myc* gene. It may be that in murine leukemia, the dual tropic virus induces an oncogene in a T-cell in the way avian leukemia virus does in the B-cell tumor of the chicken. Figure 1 shows a "minimum model" of leukemogenesis. According to this model, the critical steps are: induction of at least two different endogenous viruses; the recombinational generation of dual-tropic viruses; and, the activation of oncogenes. Chronic immune-stimulation, known to favor leukemogenesis, may affect this process by two ways: by inducing endogenous viruses, and by triggering pre-malignant changes in T-lymphocytes. There is some evidence that such changes are even required to allow T-cell infection to take place; normal T-cells which grow *in vitro* cannot be infected by retroviruses (Horak et al., 1981; Stoye and Moroni, unpublished results).

Induction of endogenous viruses

The multiple copies of endogenous viruses are integrated at different sites and apparently in many chromosomes. It appears that they have been acquired by exogenous infection, and have succeeded in maintaining themselves in the genome of the species. Over time, they have duplicated, changed their position in the genome (perhaps by reinfection of the germ line) and have given rise to the heterogeneity observed to date. It is not known why they have been maintained for long periods of time. Either they offered to their host a selective advantage of unknown nature, or they found an ecological niche as "harmless" molecular parasites, causing rare leukemias and sarcomas but not affecting the viability of the species as such. As expected, the host has evolved protection mechanisms to prevent reinfection of spontaneously induced viruses. Two such mechanisms are known: First, there is a serum lipoprotein which is highly and selectively active in neutralizing xenotropic virus. Second, mouse cells lack receptors for xenotropic virus and therefore cannot be rein-

fected once virus has become activated (Levy et al., 1975; Levy, 1978). Reinfestation by ecotropic virus is restricted by an intracellular mechanism which prevents integration of viral DNA into the host genome and is controlled by the host Fv-1 locus (Lilly and Pincus, 1973).

The induction of endogenous viruses is important for two reasons. First, it corresponds to one step in the development of retroviral leukemia. Second, it is of interest in the general context of induction and function of eukaryotic genes. The analysis of virus-induction is complicated by the heterogeneity mentioned above. If one wishes to make statements about the induction of a single provirus, care must be taken to exclude the induction of additional loci. This heterogeneity also has its merits: viruses integrated at different sites may serve as guides and probes to chromosomal regions for which no marker yet exists.

In the following sections some pertinent facts about induction of xenotropic, ecotropic and defective viruses are being summarized.

a. Xenotropic viruses

Some strains of mice (prototype NZB) spontaneously produce high titers of xenotropic viruses. A genetic analysis revealed that they carry two non-linked loci, Nzv-1 and Nzv-2, which control virus production (Datta and Schwarz, 1977). It is not known whether the lack of virus-repression results from a specific integration site, or from sequences present in the viral genome. Genetic information for a different type of xenotropic virus is present in most strains of mice, but expression is repressed. When fibroblasts from such strains, e.g. BALB/c, are treated with IrdU or BrdU, production of the repressed xenotropic virus is induced in some of the cells (Lowy et al., 1971; Aaronson et al., 1971). The mechanism for this induction is still poorly understood. Suboptimal doses of IrdU followed by UV treatment lead to virus induction, suggesting that chromosome brakes may be involved (Teich et al., 1973). Other agents which have been found to be virus-inducers in fibroblast cultures include inhibition of protein synthesis (Aaronson

and Dunn, 1974), L-canavanine (Aksamit and Long, 1977), hydroxyurea (Rascati and Tennant, 1978) and 5-azacytidine (Groudine et al., 1981; Niwa and Sugahara, 1981). We have been interested in the induction mechanisms operating in lymphocytes which are the target cells of leukemogenesis. We found that induction of xenotropic virus occurs in cells during B-cell differentiation (Moroni and Schumann, 1975; Moroni et al., 1978). This can be shown by culturing spleen-of lymphnode cells *in vitro* with B-cell mitogens, such as bacterial lipopolysaccharides, lipoprotein or tuberculin, which all trigger B-cell differentiation. Induction was enhanced by BrdU (Moroni et al., 1975). There is evidence that virus induction is linked to the process of differentiation itself: 1. When B-cell mitogens, such as dextran sulfate, lacking the capacity to induce terminal differentiation are used, no induction is seen (Moroni and Schumann, 1978). 2. CBA/N mice show a recessive sex-linked defect in B-cell differentiation. When F₁ animals in a cross with wild type mice are examined individually, only the male animals exhibit B-cell differentiation and virus-induction (Phillips et al., 1977). 3. LPS-induced B-cell differentiation can be blocked by prior treatment of B-cells with anti- μ serum. When this is done, virus induction is also impaired (Stoye and Moroni, in preparation). In a genetic cross (Stoye and Moroni, 1983) involving inducible BALB/c mice and non-inducible 129 mice, induction by mitogen as well as the BrdU-amplification effect segregated as a single trait, closely linked if not identical to the locus Bxv-1 which controls virus-induction by fibroblasts, and was discovered by Kozak and

Table 1. Cell type specificity of the induction of xenotropic and ecotropic endogenous viruses

	Xenotropic virus			Ecotropic virus		
	B-cell	T-cell	Fibroblast	B-cell	T-cell	Fibroblast
B-cell mitogen	ind.	—	—	—	—	—
T-cell mitogen	—	—	—	—	—	—
BrdU	ampl.	—	ind.	—	—	ind.

ind.: induction
ampl.: amplification
—: no effect

Rowe (1980). In our cross, we identified a second inducible locus (Bdv-1), unlinked to Bxv-1, which controls the induction of a defective virus (see below), and is also induced by LPS (Stoye and Moroni, 1983). We view Bxv-1 and Bdv-1 genes as viral markers integrated in those regions of the chromosome active in B-cell differentiation. It will be interesting to learn what cellular functions are encoded in the DNA adjacent to these viral loci.

b. Ecotropic viruses

Mice carrying ecotropic viruses fall into two groups. Some (AKR, C58) produce virus spontaneously, which leads later in life to leukemia. Other mice (BALB/c, C57Bl/6) do not express virus, but can be induced to do so by *in vitro* treatment of their fibroblasts by IrdU. Induction is controlled by a single dominant locus (Stephenson and Aaronson, 1972) mapping on chromosome 5 (Kozak and Rowe, 1979). Interestingly, no ecotropic virus is induced in B-cells under conditions that induce xenotropic virus. Table 1 summarizes the induction pattern for ecotropic and xenotropic viruses. Virus production appears to be virus type- and cell typespecific and the observed patterns raise interesting questions on the relationship between the differentiation stage of a cell and virus expression.

c. Defective viruses

Most endogenous viruses are defective and their analysis is difficult in the absence of provirus-specific assays. Eventually, monoclonal antibodies or specific DNA-probes may provide the necessary tools. The most challenging question at present is to identify and induce the (presumably defective) virus which is involved in the recombinational event which generates the leukemogenic dual-tropic virus. We have demonstrated the induction of a defective virus from strain-129 mice which lack inducible replicating viruses. With BALB/c mice, we have shown that viruses can be induced from B-cells. The first is the xenotropic virus mentioned above, the second is a defective but reverse transcriptase-positive virus. In a genetic an-

alysis, the two loci were found to segregate (Stoye and Moroni, 1983).

While T-cells cannot be induced to produce complete virus, incomplete virus expression from what appears to be defective endogenous genomes has been observed. Thymus T-cells, for example, express constitutively an antigen (G_{IX}), which corresponds to the retroviral gp70 protein (Tung et al., 1975). When mature T-cells are activated by concanavalin A, viral gp70 antigen becomes induced and inserted into the cellular membrane. This can be demonstrated by the fact that activated, but not resting T-cells can be killed by anti-gp70 antibody in the presence of complement. Interestingly, gp70-induction was shown on different subpopulations of T-cells, namely T-helper, T-suppressor, and cytotoxic T-cells (Wecker et al., 1977; Wecker and Horak, 1982; Klenner et al., 1982). As argued above for B-cells, it appears that the induced provirus in activated T-cells lies in a chromosomal region important and perhaps specific for T-cell maturation.

Using a fluorescence-activated cell sorter, Morse et al. (1979) found a gp70 molecule related to the xenotropic virus on lymphocytes of all the strains they tested. The relative amounts in different organs varied in a strain-specific way; induction of this defective virus is under host control. In conclusion, different proviral loci become expressed during the different phases of lymphocyte differentiation. This in turn may favor the recombinational event generating the leukemogenic variants and explain the observed association between leukemogenesis and hyperblastic dysfunctioning of the immune system as observed following graft-versus-host reactions (Schwartz and Beldotti, 1965).

Oncogene activation

Following infection by sarcoma- and acute leukemia viruses, the viral oncogene becomes expressed and directs malignancy. After it was realized that viral oncogenes are transduced host genes, the question arose whether these cellular host "oncogenes" - more appropriately called proto-oncogenes - might also become activated and play a role

in non-viral malignancies. Recent evidence suggests that this may be the case.

The oncogenes known at present fall into two, partially overlapping groups. The first group contains the oncogenes present in sarcoma or acute leukemia viruses. Examples are the *src* gene of Rous sarcoma virus, *myc* of avian myelocytomatosis virus, *mos* of mouse Moloney sarcoma virus. The second group contains genes which have been identified by their ability to induce foci of transformed cells following transfection into suitable fibroblast cells (NIH 3T3 cells). Many human tumor lines, but also primary human tumors contained oncogenes, as revealed by transfection experiments, amongst them lung-, colon-, bladder-mammary-tumors and leukemias (Shih et al., 1981; Murray et al., 1981; Lane et al., 1981; Lane et al., 1982; Perucho et al., 1981; Pulciani et al., 1982). The human oncogenes derived from bladder carcinomas have been cloned. They were found to be homologous to the oncogene from the Harvey sarcoma virus (Parada et al., 1982; Goldfarb et al., 1982; Santos et al., 1982).

In the following section I will summarize the evidence that cellular oncogenes become activated in cancer, and concentrate on the *myc* gene, one of the best studied examples.

The activation of the cellular *myc* gene was first shown in experiments involving avian leukosis virus (ALV). This virus, lacking an oncogene, induces B-cell lymphomas after a long latency. It turned out that the ALV genome is integrated in the tumor DNA near the cellular *myc*-gene. The integrated virus contains promoter sequences at its 3' end, which can direct transcription into flanking host sequences (Hayward et al., 1981). This induction of *myc* by nearby ALV genes is called promoter insertion. The viral promoter forms part of a larger sequence, which occurs at both ends of the integrated virus and resembles the insertion-like elements (IS) identified in prokaryotes (see Diggelmann, this volume). This suggests that integration of IS-like elements near an oncogene may trigger its expression. Indeed, Rechavi et al. (1982) recently found that one allele of the *mos* gene in a murine plasma-cytoma carried at the 5' end an insertion with direct and indirect repeats typical for IS-elements. It will be interesting to see if this ob-

servation is a general one. Evidence suggesting a possible role of the *myc* gene in human B-cell tumors has recently been presented. In man, the *myc* gene is located on chromosome 8. In Burkitt's lymphoma, as well as in other B-cell neoplasias, there is a typical translocation involving chromosomes 8 and 14, or, more rarely 8 and 22. Part of the long arm of 8 is translocated to chromosomes 14 (see Müller, this volume). Molecular cloning experiments show that in this translocation the *myc* gene, located on chromosome 8, becomes joined to the H-chain locus which is active in immunoglobulin-producing B-cells. In the more rare t (8; 22) translocation *myc* appears to become translocated to the lambda L-locus (Dalla-Favera et al., 1982; Taub et al., 1982; Nell et al., 1982). The translocation of the *myc* gene to the H-chain locus is also observed in plasmacytomas of mice which show a typical t (15; 12) translocation. In mice, *myc* is located on chromosomes 15 and the H-chain gene on chromosome 12 (Taub et al., 1982; Shen-Ong et al., 1982). In conclusion, the *myc* oncogene, known to cause experimental myelocytomatosis following MC29 virus infection is involved in a specific and virtually pathognomonic chromosome translocation in human and murine leukemias.

Activated oncogenes in human leukemias have also been detected using the NIH-3T3 transfection technique. Lane et al. (1981) described 5 oncogenes derived from human and murine T- and B-cell leukemias and lymphomas. Interestingly, different oncogenes were associated with pre-B, intermediate-B, mature-B, intermediate-T and mature-T cell tumors. It remains to be seen whether these genes are actually contributing to the malignant phenotype of these leukemias and lymphomas, or whether their activation occurs normally in differentiation and becomes "frozen" if the cell is immortalized by the transforming event.

In conclusion, the study of retroviruses and the development of suitable transfection techniques has led to the discovery of a fascinating family of genes, the oncogenes. There is hope that the elucidation of their function both in normal cells and experimental tumors will contribute to the understanding of some pathogenetic mechanisms underlying human cancer as well.

References

Aaronson, S.A., Todaro, G.J., and Scolnick, E.M. (1971) Induction of murine C-type viruses from clonal lines of virus-free BALB/3T3 cells. *Science* 174, 157-159.

Aaronson, S.A., and Dunn, C.Y. (1974) Endogenous C-type viruses BALB/c cells: frequencies of spontaneous and chemical induction. *J. Virol.* 13, 181-185.

Aaronson, S.A., and Stephenson, J.R. (1976) Endogenous type-C viruses of mammalian cells. *Biochem. Biophys. Acta* 458, 323-354.

Aksamit, R.R., and Long, C.W. (1977) Induction of endogenous murine type C virus by an arginine analog: L-canavanine. *Virology* 78, 567-570.

Dalla-Favera, R., Bregni, M., Erikson, J., Patterson, D., Gallo, R.C., and Croce, C.M. (1982) Human *c-myc onc* gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. *Proc. Natl. Acad. Sci.* 79, 7824-7827.

Datta, S.K., and Schwartz, R.S. (1977) Mendelian segregation of loci controlling xenotropic virus production in NZB crosses. *Virology* 83, 449-452.

Goldfarb, M., Shimizu, K., Perucho, M., and Wigler, M. (1982) Isolation and preliminary characterization of a human transforming gene from T24 bladder carcinoma cell. *Nature* 296, 404-409.

Gross, L. (1951) "Spontaneous" leukemia developing in C3H mice following inoculation in infancy, with Ak-leukemic extracts, or Ak-embryos. *Proc. Soc. Exp. Biol. Med.* 76, 27-32.

Groudine, M., Eisenman, R., and Weintraub, H. (1981) Chromatin structure of endogenous retroviral genomes and activation by an inhibitor of DNA methylation. *Nature* 292, 311-317.

Hartley, J.W., Wolford, N.K., Old, L.J., and Rowe, W.P. (1977) A new class of murine leukemia virus associated with development of spontaneous lymphomas. *Proc. Natl. Acad. Sci.* 74, 789-792.

Hayward, W.S., Neel, B.G., and Astrin, S.M. (1981) Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukemia. *Nature* 290, 475-480.

Horak, I., Enjuander, L., Lee, J.C., and Ihle, J.N. (1981) Resistance of cultures of normal T-cells to infection with murine C-type viruses. *J. Virol.* 37, 483-487.

Klenner, D., Horak, I., Schimpl, A., and Wecker, E. (1982) Expression of endogenous retroviral glycoprotein 70 by antigen-activated cytotoxic and suppressor T lymphocytes of mice. *Proc. Natl. Acad. Sci. USA* 79, 1250-1253.

Kozak, C.A., and Rowe, W.P. (1979) Genetic mapping of the ectropic murine leukemia virus-inducing locus of BALB/c mouse to chromosome 5. *Science* 204, 69-71.

Kozak, C.A. and Rowe, W.P. (1980) Genetic mapping of xenotropic murine leukemia virus-inducing loci in five mouse strains. *J. Exp. Med.* 152, 219-228.

Lane, M.-A., Sainten, A., and Cooper, G.M. (1981) Activation of related transforming genes in mouse and human mammary carcinomas. *Proc. Natl. Acad. Sci. USA* 78, 5185-5189.

Lane, M.-A., Sainten, A., and Cooper, G.M. (1982) Stage-specific transforming genes of human and mouse B- and T-lymphocyte neoplasia. *Cell* 28, 873-880.

Levy, J.A. (1973) Xenotropic viruses associated with NIH Swiss, NZB, and other mouse strains. *Science* 182, 1151-1153.

Levy, J.A., Ihle, J.N., Oleszko, O., and Barnes, R.D. (1975) Virus-specific neutralization by a soluble non-immunoglobulin factor found naturally in normal mouse sera. *Proc. Natl. Acad. Sci. USA* 72, 5071-5075.

Levy, J.A. (1978) Xenotropic type C-viruses. *Curr. Top. Microbiol. Immunol.* 79, 109-213.

Lowy, D.R., Rowe, W.P., Teich, N., and Hartley, J.W. (1971) Murine leukemia virus: High frequency activation *in vitro* by 5-iododeoxyuridine and 5-bromodeoxyuridine. *Science* 174, 155-156.

Moroni, Ch., and Schumann, G. (1975) Lipopolysaccharide induces C-type virus in short-term cultures of BALB/c spleen cells. *Nature* 254, 60-61.

Moroni, Ch., and Schumann, G. (1978) Mitogen induction of murine C-type viruses. IV. Effects of lipoprotein *E. coli*, pokeweed mitogen and dextran sulphate. *J. gen. Virol.* 38, 497-503.

Moroni, Ch., Stoye, J.P., DeLamarter, J.F., Erb, P., Jay, F., Jongstra, J., Martin, D., and Schumann, G. (1979) Normal B-cell activation involves endogenous retroviral antigen expression: Implications for leukemogenesis. *Cold Spring Harbor Symp. Quant. Biol.* 44, 1205-1210.

Morse, H.C.III, Chused, T.M., Boehm-Truitt, M., Mathieson, B.J., Sharro, S.O., and Hartley, J.W. (1979) Xen CSA: cell surface antigens related to the major glycoproteins (gp70) of xenotropic murine leukemia viruses. *J. Immunol.* 122, 443-454.

Murray, M.J., Shilo, B.-Z., Shih, C., Cowing, D., Hsu, H.W., and Weinberg, R.A. (1981) Three different human tumor cell lines contain different oncogenes. *Cell* 25, 355-361.

Neel, B.G., Ghanwar, S.C., Chaganti, R.S.K., and Hayward, S.W. (1982) Two human *c-onc* genes are located on the long arm of chromosome 8. *Proc. Natl. Acad. Sci. USA* 79, 7842-7846.

Niwa, O., and Sugahara, T. (1981) 5-Azacytidine induction of mouse endogenous type C virus and suppression of DNA methylation. *Proc. Natl. Acad. Sci. USA* 78, 6290-6294.

Parada, L.F., Tabin, C.J., Shih, C., and Weinberg, R.A. (1982) Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus *ras* gene. *Nature* 297, 474-478.

Perucho, M., Goldfarb, M., Shimizu, K., Lama, C., Fogh, J., and Wigler, M. (1981) Human tumor-derived cell lines contain common and different transforming genes. *Cell* 27, 467-476.

Phillips, S.M., Stephenson, J.R., and Aaronson, S.A. (1977) Genetic factors influencing mouse type-C RNA virus induction by naturally occurring B-cell mitogens. *J. Immunol.* 118, 662-666.

Pulciani, S., Santos, E., Lauver, A.V., Long, L.K., Aaronson, S.A., and Baracid, M. (1982) Oncogenes in solid human tumors. *Nature* 300, 539-542.

Rascati, R.J., and Tennant, R.W. (1978) Induction of endogenous murine retrovirus by hydroxyurea and related compounds. *Virology* 87, 208-211.

Rechavi, G., Givol, D., and Canaani, E. (1982) Activation of a cellular oncogene by DNA rearrangement: possible involvement of an IS-like element. *Nature* **300**, 607-611.

Rowe, W.P., Lloyd, M.W., and Hartley, J.W. (1980) The status of the association of MCF viruses with leukemogenesis. *Cold Spring Harbor Symp. Quant. Biol.* **44**, 1265-1268.

Santos, E., Tronick, S.R., Aaronson, S.A., Pulciani, S., and Barbacid, M. T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes. *Nature* **298**, 343-347.

Schwartz, R.S., and Beldotti, L. (1965) Malignant lymphomas following allogenic disease = transition from an immunological to a neoplastic disorder. *Science* **149**, 1511-1514.

Shen-Ong, G.L.C., Keath, E.J., Piccoli, S.P., and Cole, M.D. (1982) Novel *myc* oncogene RNA from abortive immunoglobulin-gene recombination in mouse plasmacytomas. *Cell* **31**, 443-452.

Shih, C., Padhy, L.C., Murray, M., and Weinberg, R.A. (1981) Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. *Nature* **290**, 261-264.

Stephenson, J.R., and Aaronson, S.A. (1972) A genetic locus for inducibility of C-type virus in BALB/c cells: the effect of a nonlinked regulatory gene on detection of virus after chemical activation. *Proc. Natl. Acad. Sci. USA* **69**, 2798-2801.

Stoye, J.P., and Moroni, Ch. (1983) Endogenous retrovirus expression in stimulated murine lymphocytes: identification of a new locus controlling mitogen induction of a defective virus. *J. Exp. Med.* (in press).

Taub, R., Kirsch, I., Morton, C., Lenoir, G., Swan, D., Tronick, S., Aaronson, S., and Leder, P. (1982). Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. *Proc. Natl. Acad. Sci. USA* **79**, 7837-7841.

Teich, N., Lowy, D.R., Hartley, J.W., and Rowe, W.P. (1973) Studies of mechanism of induction of infectious murine leukemia virus from AKR mouse embryo cell lines by 5-iododeoxyuridine and 5-bromodeoxyuridine. *Virology* **51**, 163-173.

Tung, J.S., Vitetta, E.S., Fleissner, E., and Boyse, E.A. (1975) Biochemical evidence linking the G_{IX} thymocyte surface antigen to the gp69/71 envelope glycoprotein of murine leukemia virus. *J. Exp. Med.* **141**, 198-205.

Wecker, E., Schimpl, A., and Hünig, T. (1977) Expression of MuLV gp71-like antigen in normal mouse spleen cells induced by antigenic stimulation. *Nature* **269**, 598-600.

Wecker, E., and Horak, I. (1982) Current topics in immunology, 98, 27-36.

Weiss, R., Teich, N., Varmus, H., Coffin, J. (Eds.) RNA Tumor Viruses. Cold Spring Harbor Laboratory, Cold Spring Harbor, 1982.

Address of the author

Dr. Christoph Moroni
Friedrich-Miescher-Institut
Postfach 2543
CH-4002 Basel (Switzerland)